TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,269,513 shares of the biopharmaceutical company’s stock after acquiring an additional 84,904 shares during the period. Charles Schwab Investment Management Inc. owned about 0.82% of TG Therapeutics worth $38,212,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. grew its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,737 shares during the last quarter. Synergy Asset Management LLC purchased a new position in TG Therapeutics during the 4th quarter worth $75,000. Finally, GAMMA Investing LLC grew its holdings in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 10.2 %

TGTX stock opened at $40.84 on Friday. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $41.85. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market cap of $6.41 billion, a PE ratio of -408.36 and a beta of 2.30. The firm’s 50-day simple moving average is $31.86 and its 200 day simple moving average is $29.04.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

TGTX has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Finally, StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.